Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/17/2008

future treatment regimens. Audience participation and Q&A are encouraged.

Schering-Plough Satellite Symposium at EASL

From Initial Therapy to a Second Chance: A Comprehensive Guide to HCV Treatment

Sunday, April 27, 8:30-10:00 a.m., Milan Convention Center, Hall B.

A world-renowned faculty will present and discuss emerging data that answer several of the most relevant questions in HCV treatment today and for the future: the most effective use of peginterferon in combination with ribavirin in initial therapy, the optimal approach to the retreatment of patients with chronic HCV for whom initial treatment was not effective, and the outlook for HCV treatment in the future. Following the scientific presentations, the faculty will engage in a panel discussion based on questions posed by the symposium attendees, providing an opportunity for dialogue around the most urgent issues facing HCV-treating clinicians today.

About Hepatitis C

Hepatitis C is a serious and potentially life-threatening disease. It is the most common blood-borne infection in America and Europe, and the most common form of liver disease, affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe.

About PEGINTRON

In the United States, PEGINTRON is indicated for use alone or with ribavirin for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.

Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL

Alpha interferons, including PEGINTRON and INTRON(R) A, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
4. Schering-Plough Reports Top-Line Results of the IDEAL Study
5. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
6. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
7. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
8. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
11. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) announced today that the US Patent and Trademark Office has allowed its patent application o
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
Breaking Medicine Technology:Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Saving Lives Is a Growth Industry 55875 1Saving Lives Is a Growth Industry 55875 2Saving Lives Is a Growth Industry 55875 3China Kangtai Cactus Biotech to Launch Patented Cactus based Low Tar Low or Zero Nicotine Cigarettes 13772 1China Kangtai Cactus Biotech to Launch Patented Cactus based Low Tar Low or Zero Nicotine Cigarettes 13772 2China Kangtai Cactus Biotech to Launch Patented Cactus based Low Tar Low or Zero Nicotine Cigarettes 13772 3Studies in animals suggest 2009 H1N1 virus may have biological advantage over seasonal influenza 55873 1Studies in animals suggest 2009 H1N1 virus may have biological advantage over seasonal influenza 55873 2
(Date:12/5/2009)--In Youngest Babies, This Type of Blood Cancer Is Most Challenging-- ,, PHILADELPHIA and NEW ORLEANS, Dec. 5 Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse w
(Date:12/5/2009)Research debunks the ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor single people who pass their 40th birthday without ever tying the knot, s
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
Breaking Medicine News(10 mins):Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
...nsible Medicine (PCRM) has developed an in-house a...the insulin level,// which is being marketed by Li...ment of the test kit during the year 2002 amid var...nd the cost and accuracy is not found to vary from...
...l study it has been found that young adults are no...ood. // This is the analysis based on a 10 year... health is better in middle-aged to older adults o... for two decades. "However, the decline is not...
...bout the health benefits of nuts but now there is ...ack a nutritional wallop — at least when eaten in ...inistration has allowed labels for most nuts to sa...ng with nuts, avocados and olive oil was more effe...
...S. Zubenko, MD, PhD, Professor of Psychiatry and B... School reported that genes relating to aging with... This research was the first of its kind and wa... men and women in the study. These individuals sho...
...ed as a wonder drug that can take care of everythi...as now emerged that it can also induce cancer cell...iversity of Pittsburgh report in the December 9 is...ecrosis factor-related apoptosis-inducing ligand (...
...ress called on Monday for more rigorous federal mo... The Food and Drug Administration (FDA) has been m...ut significant gaps remain, according to Rep. Rosa...eved to serve hospitals in all 50 states and at le...
Other Medicine News:Health News:Genetics of Ageing with Preserved Mental Capacity. 2Health News:Aspirin induces Cancer Cells To Commit Suicide 2Health News:Scrutiny Sought For Reused Devices in U.S. 2
Osher Haptic Forceps
Arruga Curved Capsule Forceps
Osher Capsule-Foreign Body Forceps
Tennant Curved Tying Forceps
Medicine Products: